在澳大利亚健康成人中开展的登革热单克隆抗体观察者盲法、随机、安慰剂对照、1期、单次递增剂量研究
在澳大利亚开展的观察者盲法、随机、安慰剂对照1期单次递增剂量研究,40名登革热初治健康成人接受1、3、7、12 mg/kg登革热单克隆抗体(VIS513)或安慰剂单次静脉给药并随访至第85天。未报告严重不良事件,安慰剂组无不良事件,抗体组34人中31人(91%)报告143例不良事件,最常见为头痛(16/34,47%)和输注反应(11/34,32%)。抗体安全且耐受良好,药代动力学暴露呈剂量比例增加,支持在登革热患者中进一步评估安全性和有效性。
要点
- 登革热单克隆抗体(VIS513)在健康成人中未报告严重不良事件
- 34名抗体受试者中31人(91%)报告不良事件,多为1级或2级并完全缓解
- 药代动力学暴露随剂量比例增加,未检测到抗药抗体
核心结论
- 登革热单克隆抗体安全且耐受良好,药代动力学暴露呈剂量比例增加,数据支持在登革热患者中进一步评估其安全性和有效性。
研究设计与样本
- 在澳大利亚开展的观察者盲法、随机、安慰剂对照、1期、单次递增剂量研究,纳入18-45岁登革热初治健康成人,无临床显著疾病或免疫抑制状况。
- 评估1 mg/kg(n=4)、3 mg/kg(n=10)、7 mg/kg(n=10)、12 mg/kg(n=10)四个剂量,除1 mg/kg队列外每队列设安慰剂对照(每队列n=2,共n=6),按剂量递增方式给药。
- 各队列内受试者先在哨兵亚队列按1:1随机,再在扩展亚队列按9:1随机分配至登革热单克隆抗体或安慰剂(1 mg/kg队列除外)。
- 40名受试者接受单次静脉注射或输注(3分钟至2小时)登革热单克隆抗体或安慰剂,随访至第85天;主要结局为给药后84天内不良事件和严重不良事件的发生比例,次要结局为药代动力学特征和抗药抗体(ADA)检测。
- 研究注册号ClinicalTrials.gov NCT03883620,所有受试者纳入安全性分析,药代动力学人群为接受登革热单克隆抗体的受试者。
主要发现
- 2019年3月22日至12月23日随机分配40名健康成人,全部完成研究;未报告严重不良事件。
- 安慰剂组6人无一报告不良事件;登革热单克隆抗体组34人中31人(91%)报告143例不良事件(1 mg/kg:4/4,100%;3 mg/kg:10/10,100%;7 mg/kg:7/10,70%;12 mg/kg:10/10,100%)。
- 143例不良事件中80例为治疗相关不良事件,涉及34人中的28人(82%);最常见为头痛(16/34,47%)、输注反应(11/34,32%)、淋巴细胞减少(7/34,21%)、乏力(5/34,15%)和发热(4/34,12%)。
- 输注反应在7 mg/kg(2/10,20%)和12 mg/kg(3/10,30%)队列中经对乙酰氨基酚预处理后较3 mg/kg队列(5/10,50%)减少。
- 大多数不良事件为1级或2级严重程度并完全缓解;中位最大血清浓度从28 μg/mL(1 mg/kg)至525 μg/mL(12 mg/kg),中位消除半衰期从775小时(1 mg/kg)至878小时(12 mg/kg),未检测到抗药抗体。
临床怎么用
- 作者认为这些数据支持在登革热患者中进一步评估登革热单克隆抗体的安全性和有效性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Dengue is highly prevalent in Asia and Latin America and has no specific dengue antiviral treatment. A recombinant monoclonal antibody (VIS513) that neutralises all four serotypes of the dengue virus has been developed in India. After confirmation of safety and efficacy in preclinical studies, it was tested in a first-in-human study to assess the safety and pharmacokinetics. METHODS: This was a partially blind (observer-blind), randomised, placebo-controlled, phase 1, single ascending dose study in Australia. Participants were dengue naive, healthy adults (aged 18-45 years) with no clinically significant disorders or immunosuppressive conditions. Four dose levels of dengue monoclonal antibody (ie, 1 mg/kg, 3 mg/kg, 7 mg/kg, and 12 mg/kg; n=4 for 1 mg/kg and n=10 each for 3 mg/kg, 7 mg/kg, and 12 mg/kg doses) were assessed in a dose-ascending way with a placebo control (n=2 for each dose cohort, total n=6) for each cohort except for 1 mg/kg. Within each cohort, participants were first randomly assigned (1:1) in a sentinel sub-cohort and then randomly assigned (9:1) in an expansion sub-cohort to dengue monoclonal antibody or placebo except for the 1 mg/kg cohort. Participants, investigators, and outcome assessors were masked and treatment administrators were not masked. 40 participants received a single intravenous injection or infusion of either dengue monoclonal antibody or placebo over a period of 3 min to 2 h and were followed up until day 85. The primary outcomes were proportion of participants with adverse events and serious adverse events (SAEs) up to 84 days after dosing whereas the secondary outcomes were to assess the pharmacokinetic profile of dengue monoclonal antibody and to assess the presence of anti-drug antibody (ADA) to dengue monoclonal antibody. All participants were included in the safety analysis and the pharmacokinetic population involved participants receiving dengue monoclonal antibody. This study is registered with ClinicalTrials.gov, NCT03883620. FINDINGS: Between March 22 and Dec 23, 2019, 40 healthy adults were randomly assigned and all completed the study. There were no SAEs reported. None of the placebo recipients (n=6) reported any adverse events. 31 (91%) of 34 participants receiving dengue monoclonal antibody reported 143 adverse events (1 mg/kg: four [100%] of four participants; 3 mg/kg: ten [100%] of ten participants; 7 mg/kg: seven [70%] of ten participants; 12 mg/kg: ten [100%] of ten participants). Of these 143 adverse events, 80 were treatment-related adverse events in 28 (82%) of 34 participants. Headache (16 [47%] of 34), infusion reaction (11 [32%] of 34), lymphopenia (seven [21%] of 34), fatigue (five [15%] of 34), and pyrexia (four [12%] of 34) were the most common reactions. Infusion reactions were reduced in the 7 mg/kg (two [20%] of ten participants) and 12 mg/kg (three [30%] of ten) cohorts with paracetamol premedication compared with the 3 mg/kg cohort (five [50%] of ten). The majority of adverse events were grade 1 or grade 2 in severity, and resolved completely. Median maximum serum concentrations ranged from 28 μg/mL (1 mg/kg) to 525 μg/mL (12 mg/kg). The median elimination half-life ranged from 775 h (1 mg/kg) to 878 h (12 mg/kg). No ADA against dengue monoclonal antibody was detected. INTERPRETATION: Dengue monoclonal antibody was safe and well tolerated. It showed a dose-proportionate increase in pharmacokinetic exposure. These data support further evaluation of dengue monoclonal antibody in patients with dengue for safety and efficacy. FUNDING: Serum Institute of India.
引用
- Gunale B, Farinola N, Kamat CD, et al. An observer-blind, randomised, placebo-controlled, phase 1, single ascending dose study of dengue monoclonal antibody in healthy adults in Australia. Lancet Infect Dis. 2024. PMID: 38408457. doi:10.1016/S1473-3099(24)00030-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。